| Literature DB >> 32946228 |
Nicoletta Brindani1, Ambra Gianotti2, Simone Giovani1, Francesca Giacomina1, Paolo Di Fruscia1, Federico Sorana1, Sine Mandrup Bertozzi3, Giuliana Ottonello3, Luca Goldoni3, Ilaria Penna1, Debora Russo1, Maria Summa3, Rosalia Bertorelli3, Loretta Ferrera2, Emanuela Pesce2, Elvira Sondo2, Luis J V Galietta4,5, Tiziano Bandiera1, Nicoletta Pedemonte2, Fabio Bertozzi1.
Abstract
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported to address the basic defects associated with CF-causing mutations, partially restoring the CFTR function in terms of protein processing and/or channel gating. Small-molecule compounds, called potentiators, are known to ameliorate the gating defect. In this study, we describe the identification of the 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole core as a novel chemotype of potentiators. In-depth structure-activity relationship studies led to the discovery of enantiomerically pure 39 endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a promising in vitro druglike profile. The in vivo characterization of γ-carboline 39 showed considerable exposure levels and good oral bioavailability, with detectable distribution to the lungs after oral administration to rats. Overall, these findings may represent an encouraging starting point to further expand this chemical class, adding a new chemotype to the existing classes of CFTR potentiators.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32946228 PMCID: PMC8011931 DOI: 10.1021/acs.jmedchem.0c01050
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446